Macaluso FS, Ventimiglia M, Fries W, et al. - Researchers carried out a three-arms propensity score-adjusted analysis applying the Inverse Probability of Treatment Weighting method, to compare the efficacy of three biologics in consecutive patients with ulcerative colitis (UC): Vedolizumab (VDZ), Adalimumab (ADA), and Golimumab (GOL). This study included 463 treatments (VDZ: n = 187; ADA: n = 168; GOL: n = 108). Median follow-up was 47.6 weeks. At 12 weeks ( n = 463), a steroid-free remission was noted in 24.1%, 33.3%, and 30.6% patients in the VDZ group, ADA group, and in the GOL group, respectively. At 52 weeks ( n = 377), a steroid-free remission was documented in 51.5%, 31.2%, and in 29.4% patients in the VDZ group, ADA group, and in the GOL group, respectively. Overall, findings revealed the superiority of VDZ over ADA and GOL at 52 weeks and as treatment persistence, while a superior treatment persistence was noted with ADA vs GOL.